GREGG/KENNEDY COMPROMISE ON FDA DRUG/DEVICE EXPORT REFORM BILL PASSES SENATE LABOR COMMITTEE BY 16-0 VOTE; MEASURE LISTS SPECIFIC COUNTRIES
Executive Summary
A compromise FDA drug/device export bill sponsored by Sens. Gregg (R-N.H.) and Kennedy (D-Mass.), the "FDA Export Reform & Enhancement Act of 1995" (S 593), was approved unanimously by the 16-member Labor & Human Resources Committee during an Aug. 2 mark-up. The compromise bill lists specific countries to which unapproved drugs and devices could be exported without FDA export approval.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: